Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6

A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir ( Sovaldi ) for people with hepatitis C genotypes 1 through 6, according to phase 2 trial results presented at the 49th annual meeting of the European Association for the Study of the Liver (EASL) last week in London....


Source Source: Aidsmap

AVAC: New issue of Px Wire: April-June, 2014

Px Wire is AVAC's quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Each issue includes news, emerging issues and features upcoming events. April-June, Volume 7, Number 2 In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in...


Source Source: AVAC

HIV-infected people may face obligatory fingerprinting in Russia

A new bill prepared by a nationalist MP and approved by federal ministries proposes the introduction of obligatory fingerprinting for all people with dangerous diseases, including HIV, and the creation of a national database. State Duma deputy Roman Khudyakov of the Liberal Democratic party told mass circulation daily Izvestia that he had prepared an amendment to the federal bill on...


Source Source: RT

Dynavax initiates Phase 3 study of HEPLISAV-B(TM)

BERKELEY, CA -- (Marketwired) -- 04/15/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was...


Therapy for hepatitis C - the costs of success

Welcomed and exciting results from three large, controlled trials of different regimens of oral antiviral agents for chronic hepatitis C, genotype 1, have now been published in the Journal ( 1-3). The regimens all included the combination of ledipasvir and sofosbuvir, two new direct-acting antiviral agents with potent activity against hepatitis C virus (HCV). The two drugs were...


Source Source: NEJM